ArticleCritical care (London, England)2011
Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis.
Article in Critical care (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- Cytokine Responses in Severe Traumatic Brain Injury: Where There Is Smoke, Is There Fire?Neurocritical care · 2019Pooled it
- Comprehensive integration of diagnostic biomarker analysis and immune cell infiltration features in sepsis via machine learning and bioinformatics techniques.Frontiers in immunology · 2025Article
- High-volume hemofiltration does not protect human kidney endothelial and tubular epithelial cells from septic plasma-induced injury.Scientific reports · 2024Article
- Predictive value of soluble CD40L combined with APACHE II score in elderly patients with sepsis in the emergency department.BMC anesthesiology · 2024Article
- Inhibition of platelet activation suppresses reactive enteric glia and mitigates intestinal barrier dysfunction during sepsis.Molecular medicine (Cambridge, Mass.) · 2022Article
- Article
- Inhibition of platelet activation suppresses reactive enteric glia and mitigates intestinal barrier dysfunction during sepsis.Molecular medicine (Cambridge, Mass.) · 2022Article
- Activated platelets and platelet-leukocyte aggregates in the equine systemic inflammatory response syndrome.Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2022Article
- Review
- Effect of antiplatelet agents onFrontiers in microbiology · 2022Review
- Persistently higher serum sCD40L levels are associated with outcome in septic patients.BMC anesthesiology · 2021Observational
- Serum Soluble CD40 Ligand in Predicting Simple Appendicitis and Complicated Appendicitis at Different Time Points in Children.Frontiers in pediatrics · 2021Article
- PMMA-Based Continuous Hemofiltration Modulated Complement Activation and Renal Dysfunction in LPS-Induced Acute Kidney Injury.Frontiers in immunology · 2021Article
- Cytokine profile in the sputum of subjects with post-tuberculosis airflow obstruction and in those with tobacco related chronic obstructive pulmonary disease.BMC immunology · 2020Article
- Role of β2 Integrins in Neutrophils and Sepsis.Infection and immunity · 2020Review
- Evidence of CD40L/CD40 pathway involvement in experimental transfusion-related acute lung injury.Scientific reports · 2019Article
- New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma.World journal of gastroenterology · 2018Review
- Platelet activation and prothrombotic properties in a mouse model of peritoneal sepsis.Scientific reports · 2018Article
- A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense.Nature communications · 2018Article
- IMMUNE CELL PHENOTYPE AND FUNCTION IN SEPSIS.Shock (Augusta, Ga.) · 2016Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
18 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCD40 Ligand (CD40L) and its soluble counterpart (sCD40L) are proteins that exhibit prothrombotic and proinflammatory properties on binding to their cell surface receptor CD40. The results of small clinical studies suggest that sCD40L levels could play a role in sepsis; however, there are no data on the association between sCD40L levels and mortality of septic patients. Thus, the aim of this study was to determine whether circulating sCD40L levels could be a marker of adverse outcome in a large cohort of patients with severe sepsis.
methodsThis was a multicenter, observational and prospective study carried out in six Spanish intensive care units. Serum levels of sCD40L, tumour necrosis factor-alpha and interleukin-10, and plasma levels of tissue factor were measured in 186 patients with severe sepsis at the time of diagnosis. Serum sCD40L was also measured in 50 age- and sex-matched controls. Survival at 30 days was used as the endpoint.
resultsCirculating sCD40L levels were significantly higher in septic patients than in controls (P = 0.01), and in non-survivors (n = 62) compared to survivors (n = 124) (P = 0.04). However, the levels of CD40L were not different regarding sepsis severity. Logistic regression analysis showed that sCD40L levels >3.5 ng/mL were associated with higher mortality at 30 days (odds ratio = 2.89; 95% confidence interval = 1.37 to 6.07; P = 0.005). The area under the curve of sCD40L levels >3.5 ng/mL as predictor of mortality at 30 days was 0.58 (95% CI = 0.51 to 0.65; P = 0.03).
conclusionsIn conclusion, circulating sCD40L levels are increased in septic patients and are independently associated with mortality in these patients; thus, its modulation could represent an attractive therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.